BACKGROUND: Cytomegalovirus (CMV)-seropositive (R+) hematopoietic cell transplant (HCT) recipients have a survival disparity compared with CMV-seronegative recipient/donor (R-D-) pairs. We hypothesized that primary letermovir prophylaxis (LET) may abrogate this disparity. We investigated the relationship between LET and mortality at 1 year post-HCT. METHODS: In this retrospective cohort study, we included adult R-D- or R+ patients who received HCT pre-LET (between 1 January 2013 through 15 December 2017) and post-LET (between 16 December 2017 through December 2019). R+ were categorized by LET receipt as R+/LET or R+/no-LET. Cox proportional hazard models were used to estimate the association of LET with all-cause mortality at 1 year after transplantation. RESULTS: Of 848 patients analyzed, 305 were R-D-, 364 R+/no-LET, and 160 R+/LET. Because of similar mortality (adjusted hazard ratio [aHR], 1.29 [95% confidence interval {CI}, .76-2.18]; P = .353]) between pre-LET/R-D- and post-LET/R-D-, R-D- were combined into 1 group. Compared with R-D-, the aHR for mortality was 1.40 (95% CI, 1.01-1.93) for R+/no-LET and 0.89 (95% CI, .57-1.41) for R+/LET. Among R+, LET was associated with decreased risk of death (aHR, 0.62 [95% CI, .40-.98]); when conventional HCT and T-cell depleted HCT were analyzed separately, the aHR was 0.86 (95% CI, .51-1.43) and 0.21 (95% CI, .07-.65), respectively. CONCLUSIONS: At 1 year post-HCT, LET was associated with closing the mortality disparity between R-D- and R+. Among all R+, LET was associated with decreased mortality, driven by 79% reduced incidence of death in T-cell depleted HCT.
BACKGROUND: Cytomegalovirus (CMV)-seropositive (R+) hematopoietic cell transplant (HCT) recipients have a survival disparity compared with CMV-seronegative recipient/donor (R-D-) pairs. We hypothesized that primary letermovir prophylaxis (LET) may abrogate this disparity. We investigated the relationship between LET and mortality at 1 year post-HCT. METHODS: In this retrospective cohort study, we included adult R-D- or R+ patients who received HCT pre-LET (between 1 January 2013 through 15 December 2017) and post-LET (between 16 December 2017 through December 2019). R+ were categorized by LET receipt as R+/LET or R+/no-LET. Cox proportional hazard models were used to estimate the association of LET with all-cause mortality at 1 year after transplantation. RESULTS: Of 848 patients analyzed, 305 were R-D-, 364 R+/no-LET, and 160 R+/LET. Because of similar mortality (adjusted hazard ratio [aHR], 1.29 [95% confidence interval {CI}, .76-2.18]; P = .353]) between pre-LET/R-D- and post-LET/R-D-, R-D- were combined into 1 group. Compared with R-D-, the aHR for mortality was 1.40 (95% CI, 1.01-1.93) for R+/no-LET and 0.89 (95% CI, .57-1.41) for R+/LET. Among R+, LET was associated with decreased risk of death (aHR, 0.62 [95% CI, .40-.98]); when conventional HCT and T-cell depleted HCT were analyzed separately, the aHR was 0.86 (95% CI, .51-1.43) and 0.21 (95% CI, .07-.65), respectively. CONCLUSIONS: At 1 year post-HCT, LET was associated with closing the mortality disparity between R-D- and R+. Among all R+, LET was associated with decreased mortality, driven by 79% reduced incidence of death in T-cell depleted HCT.
Authors: Per Ljungman; Michael Schmitt; Francisco M Marty; Johan Maertens; Roy F Chemaly; Nicholas A Kartsonis; Joan R Butterton; Hong Wan; Valerie L Teal; Kendra Sarratt; Yoshihiko Murata; Randi Y Leavitt; Cyrus Badshah Journal: Clin Infect Dis Date: 2020-04-10 Impact factor: 9.079
Authors: Susan K Seo; Kun Xiao; Yao-Ting Huang; Ubonvan Jongwutiwes; Dick Chung; Molly Maloy; Sergio Giralt; Juliet N Barker; Ann A Jakubowski; Genovefa A Papanicolaou Journal: J Infect Date: 2014-06-12 Impact factor: 6.072
Authors: Leo Luznik; Paul V O'Donnell; Heather J Symons; Allen R Chen; M Susan Leffell; Marianna Zahurak; Ted A Gooley; Steve Piantadosi; Michele Kaup; Richard F Ambinder; Carol Ann Huff; William Matsui; Javier Bolaños-Meade; Ivan Borrello; Jonathan D Powell; Elizabeth Harrington; Sandy Warnock; Mary Flowers; Robert A Brodsky; Brenda M Sandmaier; Rainer F Storb; Richard J Jones; Ephraim J Fuchs Journal: Biol Blood Marrow Transplant Date: 2008-06 Impact factor: 5.742
Authors: D Przepiorka; D Weisdorf; P Martin; H G Klingemann; P Beatty; J Hows; E D Thomas Journal: Bone Marrow Transplant Date: 1995-06 Impact factor: 5.483
Authors: Elizabeth R Duke; Brian D Williamson; Bhavesh Borate; Jonathan L Golob; Chiara Wychera; Terry Stevens-Ayers; Meei-Li Huang; Nicole Cossrow; Hong Wan; T Christopher Mast; Morgan A Marks; Mary E Flowers; Keith R Jerome; Lawrence Corey; Peter B Gilbert; Joshua T Schiffer; Michael Boeckh Journal: J Clin Invest Date: 2021-01-04 Impact factor: 14.808
Authors: Izaskun Ceberio; Sean M Devlin; Craig Sauter; Juliet N Barker; Hugo Castro-Malaspina; Sergio Giralt; Doris M Ponce; Lauren Lechner; Molly A Maloy; Jenna D Goldberg; Miguel-Angel Perales Journal: Leuk Lymphoma Date: 2014-08-06
Authors: Martin Schmidt-Hieber; Myriam Labopin; Dietrich Beelen; Liisa Volin; Gerhard Ehninger; Jürgen Finke; Gerard Socié; Rainer Schwerdtfeger; Nicolaus Kröger; Arnold Ganser; Dietger Niederwieser; Emmanuelle Polge; Igor W Blau; Mohamad Mohty Journal: Blood Date: 2013-09-13 Impact factor: 22.113
Authors: George B McDonald; Brenda M Sandmaier; Marco Mielcarek; Mohamed Sorror; Steven A Pergam; Guang-Shing Cheng; Sangeeta Hingorani; Michael Boeckh; Mary D Flowers; Stephanie J Lee; Frederick R Appelbaum; Rainer Storb; Paul J Martin; H Joachim Deeg; Gary Schoch; Ted A Gooley Journal: Ann Intern Med Date: 2020-01-21 Impact factor: 25.391